Healing in the Shadows: Cancer, Existential Distress and the Legal Paradox of Psilocybin

Written by Sterre Weaver

Each year, millions of people around the world are diagnosed with cancer, and that number is rising. Beyond the physical impact of the disease, many people also experience significant psychological distress, including anxiety, depression, and fear about the future. While mental health support is available, cancer patients often face long waiting times, limited access to appropriate care, and emotional needs that shift rapidly during treatment. It’s therefore not surprising that some begin looking for alternatives to help manage their mental health.

One alternative that has gained growing attention is psilocybin, a psychedelic substance found in certain mushrooms. Clinical trials have shown promising results, suggesting it may reduce anxiety, depression, and existential distress in people living with cancer. However, in the UK, psilocybin remains illegal and is officially classified as having no recognised medical value. This has created a gap between emerging research and real-world access. While previous studies have explored psilocybin within clinical trial settings, little is known about what happens outside of those regulated environments, including how people decide whether to use it, how they navigate its illegal status, and what it means to consider such an option while living with cancer. A current study aimed to explore those lived experiences and decision-making processes, offering insight into how patients weigh potential benefits, risks, and legality when seeking relief from psychological distress.

Read the study

The Study

In-depth qualitative interviews were conducted with seven women based in the UK with a current or previous cancer diagnosis. Four of them had taken psilocybin, while the other three had seriously considered it. After the interviews, interpretative phenomenological analysis (IPA) was used. This is a qualitative approach which aims to provide detailed examinations of personal lived experience. Lived experiences are presented in their own terms in order to fully understand how humans make sense of their own experiences. The interviews were set out to explore how participants made sense of their psychological distress, conventional mental health care, psilocybin as an option, and the illegality of the substance. Based on the interviews, three main themes were identified: 1) somatic healing needs; 2) outlawing nature: illegality as both a burden and boundary; and 3) reconnecting self, nature and mortality.

Somatic Healing Needs

Participants described that after a cancer diagnosis, the emotional impact was immediate, overwhelming, and deeply connected to their physical experience of illness. Several spoke about feeling shocked, numb, fearful, or disconnected from their bodies, as if their sense of self and future had suddenly collapsed. Rather than seeing these reactions as mental health problems, they were understood as natural responses to a real threat to their lives: their bodies trying to process trauma and survive. However, participants often felt that conventional mental health care didn’t recognise or support this kind of whole-body distress. Psychological support was described as limited, delayed, or focused on managing symptoms rather than helping them process the root shock and existential fear of their diagnosis. Some felt unable to talk openly about death or were quickly offered antidepressants, which they experienced as emotionally numbing and impractical given the amount of medication they were already given. Overall, participants expressed a strong need for support that acknowledged the deep connection between mind and body and allowed them to fully feel, understand, and integrate their experience, rather than suppress or medicalise it. In this context, psilocybin was considered as a way of addressing the ‘root’ of the issue rather than the symptoms, referring to the shock, trauma and mortality itself.

Outlawing Nature: Illegality as Both Burden and Boundary

Participants described feeling frustrated and conflicted about psilocybin being illegal, especially when they experienced it as natural, healing, and deeply meaningful. For many, using psilocybin was not about rebellion but about trying to meet emotional needs that conventional mental health care had failed to address. They felt it was contradictory that antidepressants were easily prescribed, while a naturally occurring substance they perceived as transformative was criminalised. The illegality added extra stress to an already vulnerable time in their lives, creating anxiety about safety, dosage, sourcing, and lack of professional support. Some felt angry that something they believed could ease existential fear was inaccessible or stigmatised. At the same time, participants were not naive about the risks: illegality pushed them into isolated decision-making and unregulated spaces. However, legalisation was not seen as a simple solution either. While some believed it would improve safety and legitimacy, others worried that government or pharmaceutical control would strip psilocybin of its sacred, relational, and contextual aspects, reducing it to just another medical product. Overall, participants experienced a tension between illegality as a harmful barrier and legalisation as a potential threat to the meaning and integrity of the healing experience.

Reconnecting Self, Nature, and Mortality

Participants described a strong need to reconnect with themselves after cancer had left them feeling emotionally and physically fragmented. Many felt that healing wasn’t just about reducing distress, but about rebuilding a sense of connection between their mind, body, identity, and the natural world. They were often drawn instinctively toward nature based or body-focused practices, such as spending time outdoors, as a way to process overwhelming emotions. Psilocybin was seen by several as something that could support this reconnection by helping them face, feel, and release difficult emotions rather than suppress them. Those who had taken it described feeling more peaceful, emotionally open, and able to experience beauty, forgiveness, or wholeness again. It also appeared to change their relationship with death: while fear didn’t disappear entirely, it became less overwhelming and less central to daily life. Participants spoke about feeling more able to accept mortality without being consumed by it. Overall, psilocybin was understood not as a cure, but as a potential way to reconnect with themselves, their bodies, and the reality of death in a calmer and more meaningful way.

Why This Study Matters

The current study has looked beyond tightly controlled clinical trials and explored how people outside of that context think about and make decisions around psilocybin when facing the emotional impact of cancer. Instead of focusing on whether psilocybin “works” in a clinical sense, it highlights questions of acceptability, trust, moral reasoning, and what people do when their emotional and existential needs aren’t being met by current care. Participants described the added emotional and practical burden created by prohibition, including anxiety around safety, sourcing, and lack of emotional support, suggesting that criminalisation may actually increase vulnerability by pushing people toward unregulated routes. At a time when several countries are introducing compassionate access schemes, the UK remains highly restrictive. These findings suggest that existential distress in oncology may not be adequately addressed within existing pathways, and that policy and clinical decisions should consider more than symptom reduction alone, including meaning-making, spiritual wellbeing, and long-term integration. Given this population’s evident unmet clinical need, a compassionate access scheme to improve the mental health of people with cancer is timely.